Navigation Links
InterMune Announces Issuance of U.S. Patent for ITMN-191
Date:2/19/2009

BRISBANE, Calif., Feb. 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the issuance of U.S. Patent Number 7,491,794, a composition of matter patent which covers the ITMN-191 (R7227) compound. The nominal 20-year patent term extends to October 13, 2024. ITMN-191 is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are pleased to announce that this new patent, which is the foundation of our intellectual property coverage of ITMN-191, has issued. We look forward to continued progress in developing ITMN-191 with our partner, Roche, as we anticipate the start of our Phase 2b program in the second quarter of 2009."

About ITMN-191 (R7227)

ITMN-191 is being developed with InterMune's collaborative partner, Roche, for the treatment of patients chronically infected with HCV. On January 12, 2009, InterMune announced top-line results from a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). InterMune reported that after 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. Reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment in any cohort. ITMN-191 was generally safe and well tolerated in the study. There were no serious adverse events or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the AE profile of standard of care (SOC), and none led to trea
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... (OTC Bulletin Board: WDST ) ( www.Regenicin.com ... Christopher A. Hadsall, whose primary responsibilities will be to ... as Chief Operating Officer.  Mr. Hadsall brings 12 years ... instrumental in working with various military groups to build ...
... Texas, Oct. 5 C3i, the leader in technology ... (BMS), a leading global biopharmaceutical company, will deliver a ... the newest version of Oracle Clinical/Remote Data Capture (OCRDC) ... the Oracle Health Sciences User Group conference (OHSUG) in ...
... Technologies, Inc. (ISTO), an  orthobiologics company with a cell-based ... patient enrollment in the Phase I clinical study for ... designed for the treatment of discogenic back pain. The ... All patients enrolled in the trial suffered from persistent ...
Cached Biology Technology:Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3
(Date:4/20/2014)... Stem cells the body,s master cells demonstrate ... level, according to a study published today from scientists ... as auxeticity is one which may have application ... Most materials when stretched will contract. For example, if ... will get thinner. The opposite is also true: squeeze ...
(Date:4/20/2014)... pancreatic cancers also promote drug-resistance and ultimately spur tumor ... School of Medicine have discovered a molecule, or biomarker, ... appears responsible for inducing tumor metastasis by enhancing the ... findings, published in the April 20, 2014 online issue ... new therapeutic opportunities for reversing drug resistance in a ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... key step toward providing patients with treatments based on their ... Genomics Consortium (IGC) have launched a new joint venture that ... Called Paradigm, the new nonprofit company brings together the expertise ... using genetic information to understand and treat disease. Beginning ...
... Aug. 16, 2012 Reportlinker.com announces that ... in its catalogue: Booming ... http://www.reportlinker.com/p0946283/Booming-CCTV-Market-in-Asia-Forecast-to-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... market has been experiencing significant growth due ...
... Aug. 15, 2012 DNA sequencing is rapidly getting faster ... patients will be able to use this information. In ... from around the world are vying to interpret the ... cause remains a mystery—with the goal of establishing "best ...
Cached Biology News:Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics 2Booming CCTV Market in Asia Forecast to 2014 2Booming CCTV Market in Asia Forecast to 2014 3Thirty teams compete to interpret three families' genomes 2Thirty teams compete to interpret three families' genomes 3Thirty teams compete to interpret three families' genomes 4Thirty teams compete to interpret three families' genomes 5
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... Extracts are optimized for maximum packaging efficiencies ... high efficiency extracts (> 109 pfu/g with ... a library containing at least 5 ... extracts are made from a specially designed ...
... Panorama Mouse/Rat Tissue Extract Protein Array Kit ... various tissue extracts. The expression of a ... a protein specific antibody. When the antibody ... by a sensitive chemiluminescent or fluorescent signal ...
... offers pre-validated SNP sequencing ... amplicons within 93 genes ... and more than 80 ... assays were developed and ...
Biology Products: